Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Xiuning
X
Le
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Jason A
JA
Freed
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Paul A
PA
VanderLaan
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Mark S
MS
Huberman
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Deepa
D
Rangachari
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Susan E
SE
Jorge
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Antonio R
AR
Lucena-Araujo
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Susumu S
SS
Kobayashi
Foundation Medicine, Inc, Cambridge, MA.
Sohail
S
Balasubramanian
Foundation Medicine, Inc, Cambridge, MA.
Jie
J
He
Foundation Medicine, Inc, Cambridge, MA.
Yakov
Y
Chudnovsky
Foundation Medicine, Inc, Cambridge, MA.
Vincent A
VA
Miller
Foundation Medicine, Inc, Cambridge, MA.
Siraj M
SM
Ali
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: dbcosta@bidmc.harvard.edu.
Daniel B
DB
Costa
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077547:Crizotinib; D005260:Female; D023281:Genomics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D019859:Proto-Oncogene Proteins c-met; C062333:ROS1 protein, human; D020794:Receptor Protein-Tyrosine Kinases
Anaplastic lymphoma kinase; C-ros oncogene 1; Hepatocyte growth factor receptor; Mutation; Next-generation sequencing